Mizuho raises Elevance Health price target to $465
Mizuho analyst Ann Hynes maintained an Outperform rating on Elevance Health and increased the price target to $465 from $435, signaling confidence in the stock's future performance.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Ann Hynes has maintained an Outperform rating on Elevance Health and raised the price target to $465 from $435. The adjustment reflects a revised outlook on the company's stock performance.
Rating and Target Details
The research update highlights the analyst's continued confidence in Elevance Health. The new price target represents an increase over the previous target of $435.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $435 |
| New Price Target | $465 |
What specific factors are driving the revised outlook for Elevance Health's stock performance?
How might this price target increase influence investor sentiment towards the healthcare sector?
What potential risks could impact Elevance Health's ability to meet the new $465 price target?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
